What domestic pharmaceuticals JP Morgan paid attention to?

Held 39 conferences from the 11th local time, announced the main track of Samsung Biologics

Celltrion did not attend, and Crystal Genomics challenges technology export

Will a domestic company that can export technology be created in the midst of the prolonged COVID-19 crisis?

More than 20 domestic pharmaceutical and bio companies are invited to the world's largest pharmaceutical and bio industry event, annual J.P.

 

Morgan Healthcare Conference.

 

According to the pharmaceutical industry on the 8th, more than 20 domestic pharmaceutical and bio companies, including Samsung Biologics and Hanmi, will participate in the J.P.

 

Morgan Healthcare Conference.

 

which will be held from the 11th to the 14th local time in San Francisco, USA.

 

It is 39th event where about 500 large global pharmaceutical companies as well as domestic companies participate in the event to share new R&D achievements and status, and discuss the future direction of the pharmaceutical and bio industry.

 

It can be an opportunity for domestic pharmaceutical and bio companies to achieve the greatest goals of technology export and partnership signing.

 

A representative example of domestic companies that will attend the conference is Samsung Biologics.

 

It is the only domestic company in charge of the announcement of the Main Track scheduled for the 13th, and the new CEO John Rim will introduce the company's main business details and vision.

 

Celltrion, known as a regular customer of the conference among domestic companies, is expected to be absent from this event.

 

It is the intention to focus on the development of the COVID-19 antibody treatment that is currently being promoted, and the results of the global phase II clinical trial will be announced on the 13th.

 

Companies presenting at the subsidiary session Emerging Market are Hanmi, LG Chem, Hugel, HK inno.N, and Genexine.

 

Hugel, which participated in the conference for the second consecutive year, presented ‘2020 achievements and vision for 2025' based on the success secret of 'Letybo', a botulinum toxin that was recently approved in China, while major overseas institutional investors during the conference.

 

It will also hold 1:1 meetings with institutional investors.

 

Genexine is planning to introduce the business strategy of 'Continuous Interleukin 7 (GX-I7)', which is also being developed as an anticancer drug and COVID-19 treatment at this event.

 

HK inno.N, participating for the first time, plans to introduce autoimmune disease treatment and non-alcoholic steatohepatitis, including K-CAB Tab.

 

LG Chem also decided to disclose its business strategy, including the new drug pipeline.

 

LG Chem is currently conducting phase II gout treatment, phase II treatment for autoimmune diseases, phase I treatment for rare obesity, and phase I treatment for non-alcoholic steatohepatitis.

 

There are various pharmaceutical and bio companies that do not make presentations, but participate in conference meetings.

 

JW-Pharma, Crystal Genomics, Genome & Company, Shaperon, SCM Life Science, AptaBio, MedPacto, ABL bio, Syntekabio, Pharmabcine, Cellivery, KoBioLabs, Oscotec.

 

JW-Pharma decided to introduce research projects through video meetings and conduct one-on-one partnership consultations and consultation meetings for joint research with global investment companies including multinational companies.

 

In particular, JW-Pharma plans to take this opportunity to discuss additional global technology alliance projects for URC102, a gout treatment that has been successfully exported last year and has been recognized in the global market.

 

Pharmabcine will introduce major pipelines, including Olinvacimab, and plan to jointly research materials and transfer technologies.

 

An official from a pharmaceutical company participating in the conference said, “It is difficult to be sure that the progression online will lead to the creation of results such as the export of Lazertinib technology.

 

Nevertheless, global pharmaceutical companies and investors will be informed of differentiated competitiveness to develop even in COVID-19 situation.”